Thank the (sic) advance to Annual the Gene next-generation preclinical important with platform. you everyone joining American we you, Cell Gene Therapy & provides and These epigenetic have Therapy I'm potential Society presenting where to Louise, capabilities, from and believe our depth good Cell American of capsid Meeting and in showcase very partners. power afternoon scientific Society our be and to we pleased [ Sangamo's to of platform genomic the both speaking today data data ourselves call. AAV neurology Baltimore, been pipeline delivery which from programs regulators, of and the of opportunities strong engineering ]
offering and for with significant in $XX our raised of gross institutional science shareholders, thankful support In funding compelling to late leadership programs, pleased order The In laser-focused proceeds. to a and a their are million announce on including these an been needs. approximately capitalized. was and we must have are be our I important existing addressing team development, investor mission. Sangamo our direct we This March, that registered progress well
being Business That with pleased development important these be would front. progress on am That position to first long-term #X this emphasize the the continues for funding. was, my success. of made efforts, additional I securing we Sangamo that priority. our to in resolutely to is upon and foundation on I is part like this however, step an building focused journey current are to that
next-generation portfolio, Fabry genome novel product our engaged engineering very including conversations potential candidates We encouraging capsid, our across program, and multiple are capabilities. STAC-BBB engineered partners neurology disease our our currently in with preclinical our
of of we this are are any potential these Be until neurology, hear progress to preclinical one important concrete hope science transaction focus our data important solidify that finalized. addressing news discussions to and months, to differentiated has unable front, to and our dedicate in more ourselves disorders. more sharpened this transactions. that we announce on or the news is validate desire more but decision made neurological Over your Sangamo share assured help we understand presented recent encouraged to contextualize by why I
the barrier robust capsid variants outperformed AAVX other March, and our XXX-fold primates. expression to demonstrated the showed share blood-brain higher were the in This brain remarkable blood-brain AAV capsid of barrier novel In penetration capsid, to in neurons in industry-leading evaluated all we with intravenously preclinical known proud neurotrophic nonhuman and administered penetration from data transgene benchmark new published STAC-BBB which compared capsid transduction study.
the of potent and our repression prion tau areas, robust cargo, showed to XXXX. with support tau genes prion submission and which prion brain neurons and clinic we end key advancement the modify with disease zinc-finger epigenetic and in disease potent progression programs, Combined tauopathies. all are These various the to across of exciting our observed of data on the expression of regulation track by regulatory further cargo widespread for STAC-BBB sent we potential mediated illustrating and
neuropathic significant candidate expected uses we fourth quarter ability the our our IND year. in continue in to advance to an pain, towards established We submission which Meanwhile, believe an intrathecally NavX.X, to new combine of chronic lead administered treatment exciting of capsid this indications system for has delivery treatments nervous potent historically central challenging. the capsid devastating the regulation industry-leading technology diseases, for of unlock proved zinc-finger potential epigenetic payloads neurological delivery which with could
genome zinc-finger X advances Building presentations this and delivery These XX presentations large-scale enable capsid platform, potentially of week's be various we technology Annual of next-generation presenting including ASGCT our proud technology to engineered regulation posters our to discovery editing. on Meeting. the for transformative neurology and pipeline, the in at integrase depth showcase exciting this, platform are our epigenetic applications
syndrome, range In epigenetic regulation, type as Phelan-McDermid ALS, potential prion and SODX-mediated neurological XA tauopathies, lateral disease, sclerosis Syndrome, XA, advances we repressors many diseases, have Angelman treatment Parkinson's Charcot-Marie-Tooth and in zinc-finger syndrome of activators disease, and neurological the remarkable other shared of a amyotrophic disorders. or Dravet for such diseases,
through Sangamo's demonstrated developed engineering capabilities also our SIFTER. have platform, AAV capsid delivery potent We
Here, we STAC-BBB tau repression STAC-BBB including findings, delivery. via prion have data presented additional and achieved
a findings mechanism STAC-BBB barrier. first for presented cross exciting also how time blood-brain possible We the for initial supporting the may
Our intrathecal SIFTER of as and for capsid engineer can in-vitro SIFTER discovery. also to engineer designed for intravenous delivery. various routes platform administration, is capsids such
tomorrow, epigenetic easily present platform of screening will STAC-XXX, We a believe neurons the in STAC-XXX, highly findings throughput help novel regulators. presentation to potent in we a accelerate small enables transcriptional from been the will high So regulators. we potent highly specific scale, anticipate that's capsid manufacturers at which and be discovery shown of neurology-focused and
gene. platform, that for the derived time we integrating deep new potentially potentially the approach our on in the interactions for in in for into years. with patients who a people this DNA protein-DNA a sequences breakthrough single many of site has chromosomal to for constructs genome building first Precisely unique synthetic DNA large Finally, have expertise large field dream integrating medicine working a been presented desirable mutations same our from zinc-finger treat into the
MINT Sangamo's versatile Our editing modular that serine a method toolbox BxbX, platform or editing understands adds a genes or engineers guided capabilities. genome of integrase recombinase and to and protein replace insert is entire to
natural a MINT in used correct a our that mutations its locus. hopeful to inserting patient gene disease-causing many into are by population copy diverse be correct of the could platform We
various internally agricultural in deployed indications, biotech be and provide for also could disease opportunities, partnering settings. potential but both human neurological MINTs for
partners provide are that active our We about opportunity. integrase capabilities could funding MINT in with nondilutive another discussions potential and hopeful are with us already potential
available Alongside in the about which more our I BioArchive to Publications advancements, also have topic at this integrase in in genomic you ASGCT learn on presentations exciting next-generation a we also is field further this these of manuscript week, website. page development the the of this published medicines. outlining encourage
our looking programs. Now clinical at
quarter dosed, Fabry STAAR With program, the made study in treatment final patients began The on Fabry additional to the patient have total of dosed dosed the enrollment has have now the been place Phase or from in appropriate the our gene at are having already We to of therapy study treatment patients for since advances resulting stop time. February in ERT, therapy, the withdraw of withdrawn enzyme strong patient a in complete. able and disease. I/II ER XX civaparvovec, XX who ERT XXXX, dosing to ERT, screening, remaining X isaralgagene date. plans One replacement patients for disease investigational our first
the we disease. updated Annual February, differentiated compelling and benefit results sustained profile. preliminary showing Symposium study single STAAR World Fabry underscore a presented At a potential These in treatment the as clinical XXth for program's data safety from the administration
on As regulatory with Medicines U.S. an abbreviated we announced the granted We've agency. ILAP potential FDA pathway U.K. the care European medicine prime eligibility and to also this the designation by health by Agency, been approval. a and reminder, products quarter, alignment
additional defer registrational a our with this or potential discussions a We financing disease are continue for engaged is collaborator partnership in in program trial Fabry and to for secured. partners program potential planning until collaboration for active investments
XXXX clinical forward anticipates license an gene authorization severe pivotal the look a moderately Moving to early giroctogene program. expected pivotal is A. severe if AFFINE to therapy We fitelparvovec, application partner readout the Phase mid-XXXX submitting developing patients the with to of marketing we're in Pfizer application in investigational in trial III for with hemophilia our Pfizer supportive. readout and biologics a
from ended up equivalents, royalties million and As available payments eligible the sales $XX includes which from million on to a and expected of aforementioned XX% in reminder, cash reduction approximately to XXXX. with we the potential the offering. XX% third earn will $XXX We to believe program. sufficient these the to are these workforce milestone from cash up in cost potential planned funds our quarter this fund recent savings reductions registered We resources with in other to direct quarter operations restructurings, cost combination into and be
are we across required reality. a transform science to We As discussions make additional raise potentially with to engineering to range and Fabry raising required lives as options and committed pursuing our are conditions are program, encouraged has efforts. living devastating a our capsid important funding company to development different actively by earlier, seek I engineering ongoing believe patients our the capital neurological the of a next-generation of vision we and outlined genome business the
for open questions. please Operator, the lines
